Keywords
Myocarditis
Neoplasms
Antineoplastic agent
Immunotherapy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe, from the scientific literature, myocarditis as cardiotoxicity resulting from the use of chemotherapy and immunotherapy in cancer patients. Methods: An integrative literature review study of a qualitative nature with an exploratory descriptive approach. The following databases were used Scielo, Pubmed and Scopus. Data analysis included pre-analysis, material exploration and data processing. After the critical analysis, the studies were selected for analysis and analysis for the definition and composition of the analytical categories that answered the north question of the question. Results: Ten articles were found consistent with our objective. Both chemotherapy and immunotherapy are treatments that are common in cancer patients. Final considerations: It was possible to consider the main points of relationship between chemotherapeutic and immunotherapeutic oncology and cardiovascular effects. Cardiotoxicity is one of the most significant adverse events during cancer treatment, being responsible for complications in cancer patients. Myocarditis has emerged as a serious toxicity associated with antineoplastic treatment, although it appears to be infrequent cases.
References
AMMIRATI E, et al. “Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.” Circulation Heart failure, 2020; 13(11): e007405.
BRAHMER JR, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018; 36(17): 1714-1768.
CHEN DY, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. Journal of Formosan Medical Association, 2020; 119(10): 1461-1475.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2020: incidência de câncer no Brasil. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf. Acessado em: 20 de maio de 2022.
HAJJAR LA, et al. Diretriz Brasileira de Cardio-oncologia – 2020. Arquivos Brasileiros de Cardiologia, 2020; 115(5): 1006-1043.
HERRMANN J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol, 2020; 17(8): 474-502.
HU JR, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019; 115(5): 854-868.
KWAN JM, et al. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Frontier in Cardiovascular Medicine, 2022; 9: 829553
LYON AR, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal Heart Failure, 2020; 22(11): 1945-1960.
MINAYO MCS. Análise qualitativa: teoria, etapas e fidedignidade. Ciências e saúde coletiva (Internet), 2012; 17(3): 621-626.
MORE LA, et al. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death. Currients Cardiology Reports, 2021; 23(3): 17.
MOSLEHI J, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391(10124): 933.
MOSLEHI J, et al. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. Journal of Clinical Investigation, 2021; 131(5): e145186.
NOWSHEEN S, et al. Trastuzumab in Female Breast Cancer Patients with Reduced Left Ventricular Ejection Fraction. Journal of The American Heart Association, 2018; 7(15): 1-12.
ROMITAN DM, et al. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines, 2020; 8(11): 496.
SÁNCHEZ MD, MILIÁN MB. Sinais elétricos de arritmias ventriculares malignas e morte súbita: importância em pacientes recebendo terapia anticâncer. Revista Cubana do Cardiologia y Cirurgia Cardiovascular, 2020; 23(15): 1-5.
SILVA PGMP, et al. Cardiotoxicidade associada à terapia quimioterápica oncológica: Identificação dos fatores de risco. Research, Society and Development, 2021; 10(2): e9110212299.
SURY K, et al. Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol, 2018; 14: 571–588.
WILCOX NS, et al. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circulation Research, 2022; 130(4): 632-651.
YUAN M, et al. The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis. Cardiovascular Therapeutics, 2018; 36(6): 12475-1280.